title: Verteporfin therapy for CNV secondary to OHS.
authors.forename: David A
authors.initials: DA
authors.lastname: Saperstein
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Rosenfeld
authors.forename: Neil M
authors.initials: NM
authors.lastname: Bressler
authors.forename: Robert H
authors.initials: RH
authors.lastname: Rosa
authors.forename: Paul
authors.initials: P
authors.lastname: Sternberg
authors.forename: Thomas M
authors.initials: TM
authors.lastname: Aaberg
authors.forename: Thomas M
authors.initials: TM
authors.lastname: Aaberg
authors.forename: Annemarie
authors.initials: A
authors.lastname: Weisberger
mesh_terms: D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D015821:Eye Infections, Fungal / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006660:Histoplasmosis / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D011446:Prospective Studies; D019233:Retreatment; D013577:Syndrome; D000077362:Verteporfin; D014792:Visual Acuity
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin